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IL-17A Monoclonal Antibody Partly Reverses
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Min Zhang,1,2 and Xin Zhou1,2
Abstract—Exposure to ozone has been associated with airway inflammation and glucocorticoid insensitivity.
This study aimed to observe the capacity of anti-murine interleukin-17Amonoclonal antibody (IL-17mAb) to
reverse ozone-induced glucocorticoid insensitivity and to detect its effects with glucocorticoids in protecting
against airway inflammation. After C57/BL6 mice were exposed to ozone (2.5 ppm; 3 h) for 12 times over
6 weeks, PBS, IL-17mAb (50 ug/ml), dexamethasone (2 mg/kg), and combination administration of IL-
17mAb (50 ug/ml) and dexamethasone (2mg/kg)were intraperitoneally injected intomice at a dose of 0.1ml,
respectively, for 10 times over 5 weeks. At sacrifice, lung histology, airway inflammatory cells, levels of
related cytokines in bronchoalveolar lavage fluid (BALF), and serum were analyzed, airway inflammatory
cell infiltration density and mean linear intercept (Lm) were measured, the expression of IL-17A mRNA,
glucocorticoid receptors (GR), NF-κB, and p38 mitogen-activated protein kinase (MAPK) phosphorylation
were determined. We found that combination administration markedly reduced ozone-induced total inflam-
matory cells, especially neutrophils; inhibited levels of cytokines, including IL-8, IL-17A, and TNF-α in
BALF; and suppressed airway inflammatory cell infiltration density and Lm. Additionally, combination
administration significantly elevated levels of IFN-γ inBALF, decreased the dexamethasone-induced increase
of IL-17A mRNA, and increased the expression of GR and decrement of NF-κB and p38MAPK phosphor-
ylation, which are also related to glucocorticoids insensitivity. Collectively, combination administration shows
profound efficacy in inhibiting certain cytokines, and IL-17 mAb partly improved the glucocorticoids
insensitivity via modulating the enhanced production rate and improving expression of IL-17A induced by
glucocorticoids administration and p38MAPK, NF-κB signaling pathway.
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BACKGROUND
Ozone (O3) is an exogenous oxidant which adversely
affects human health by irritating the mucosa and harming
the respiratory system [2]. Oxidative stress and its products
are involved in the mechanism underlying ozone-induced
inflammation, induce and amplify the bronchial hyperres-
ponsiveness [3, 14]. Oxidative stress is also a feature of the
airways, resulting from the release of reactive oxygen and
nitrogen species from inflammatory and immune cells in
the airways [14], and plays an important role in the path-
ogenesis of chronic obstructive pulmonary disease
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(COPD) [13, 40, 42] and in the induction of glucocorti-
coids insensitivity. The mechanisms and pathways by
which oxidative stress can lead to chronic inflammation
and emphysema have been investigated in mouse models
of cigarette exposure [44, 48]. Furthermore, direct expo-
sure of mice to an oxidant gas, ozone, results in emphyse-
ma and chronic lung inflammation reminiscent of COPD
[50]. Experimental ozone exposure at high concentrations
can also induce bronchial hyperresponsiveness resulting
from an increase in contractility of the airways [27, 45].
Glucocorticoids, characteristic of anti-inflammatory
and immunosuppressive actions [10, 41], are the mainstay
for the treatment of chronic inflammatory diseases includ-
ing asthma and COPD. However, it has been recognized
that certain patients do not respond well to glucocorticoids
treatment and at high risk of adverse effects [5, 22]. Several
mechanisms may underlie the reduced glucocorticoids sen-
sitivity, namely, glucocorticoids insensitivity, which is in-
fluenced by multiple factors [8], including the role of the
mitogen-activated protein kinases (MAPK) [12, 28], de-
fective histone acetylation, and GR modification [6]. Glu-
cocorticoids insensitivity is also a feature of other immune
and inflammatory disease, including rheumatoid arthritis,
inflammatory bowel disease, and systemic lupus erythe-
matosis [6].
Interleukin (IL)-17, also known as IL-17A, is pro-
duced by CD4+ Th17 cell [46], cytotoxic T cells,
invariant natural killer T cells [33], lymphoid tissue-
inducer like cells [47, 53], and CD8+ T cells [11]. IL-17A
induces the release of the pro-inflammatory cytokines, IL-
8, CXCL1, KC, GCSF, and GM-CSF from the airway
epithelial cells, smooth muscle cells, and macrophages
and thereby orchestrates neutrophilic inflammation and
release of reactive oxygen species [53, 56]. The previous
investigations also showed that IL-17A contributed to ste-
roid insensitivity in patients with severe asthma [54]. Thus,
IL-17A may be involved in corticosteroid responses to
oxidant stress and IL-17A expression may underlie gluco-
corticoids insensitivity found in patients with severe asth-
ma and COPD. However, few investigations have been
conducted to determine whether the oxidant-mediated dis-
ruption of the combination administration of IL-17mAb
and glucocorticoids contributes to reversing the corticoste-
roid insensitivity.
In regard to the high risk of adverse effects of
glucocorticoids including diabetogenesis, osteoporosis,
muscle wasting, skin thinning and weight gain [1, 30],
and the above noted corticosteroid insensitivity, more
effective anti-inflammatory therapeutic approaches are
needed to explore. So, we used a mouse model of
chronic exposure to ozone that leads to airway inflam-
mation and lung destruction, to investigate whether
IL-17mAb can overcome the glucocort icoids
insensitivity.
METHODS
Mice and Ozone Exposure
Pathogen-free, 10∼12-week-old male C57/BL6
mice, obtained from Shanghai Laboratory Animal
Center, were housed within filter-topped cages, main-
tained in a controlled temperature (19∼23 °C) and
humidity (40∼60%), facility with a strict 12-h light-
dark cycle and were given free access to food and
water. According to random number table, mice are
divided into four parts: ozone–exposed + PBS-treated
model, ozone–exposed + PBS-treated + dexametha-
sone-treated model, ozone-exposed + IL-17 mAb-
treated model, ozone–exposed + IL-17mAb-treated +
dexamethasone-treated model. Animals were exposed
to ozone produced from an ozoniser (Model 500
Sander Ozoniser, Germany), mixed with air, for 3 h
at a concentration 2.5 parts per million (ppm) in a
sealed Perspex container, twice a week for 6 weeks.
Control animals received medical air only over the
equivalent period. Ozone concentration was continu-
ously monitored with an ozone probe (ATi Technolo-
gies, Ashton-U-Lyne, UK). From day 42, mice were
injected intraperitoneally with IL-17mAb (2 mg/kg,
0.1 ml), dexamethasone (2 mg/kg, 0.1 ml), or vehicle
1 h before ozone exposure for 10 times. All the
animal experiments were strictly conducted in accor-
dance with the protocols approved by the Ethics Com-
mittee for Animal Studies at Shanghai General Hos-
pital, China. All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to
minimize suffering.
Bronchoalveolar Lavage Fluid (BALF) and Cell
Counting
Immediately after the assessment of airway reactivity,
mice were sacrificed after anesthesia with an overdose of
pentobarbitone (500 mg/kg intraperitoneally). The tracheal
was exposed and intubated with PE-60 tubing (0.72-mm-
inner diameter, 1.22-mm-outer diameter). BALF samples
were obtained as described previously [50]. Briefly, mice
were lavaged with three aliquots of 0.3 ml sterilized saline
and BALF was retrieved. Return volume was recorded and
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was consistently >80% of the instilled volume. The BALF
was then centrifuged at ×1500g for 10 min at 4 °C. The
supernatant was stored at −80 °C for further assay. Total
differential cell counts were determined under a micro-
scope. The remaining cell pellet was resuspended in 1 ml
PBS solution. Total cell counts were determined using a
haemocytometry, by adding 100 μl of the cell suspension
to 100 μl trypan blue stain. Differential cell counts were
performed on cytocentrifuge preparations (Cytospin 2;
Shandon, UK) stained with Wright-Giemsa by counting
approximately 400 cells under ×400 magnification from
each individual of four different random locations by two
independent, blinded investigators.
Bronchoalveolar Lavage and Measurements of BALF
Cytokines
All the cytokines, including interleukin (IL)-8, IL-
17A, interferon (IFN)-γ in both supernatants of BALF
and serum, and tumor necrosis factor (TNF)-α in BALF
were determined by enzyme-linked immunosorbent assay
(ELISA), as previously described [58]. Measurements of
IL-8, IL-17A, IFN-γ, and TNF-α concentrations were
performed in lung homogenate supernatants with commer-
cial available ELISA kits (R&D Systems China Co., Ltd.,
Shanghai, China) and were performed according to manu-
facturer’s instructions.
Histological and Morphometric Analysis
After BALF, the left lung lobe was removed and fixed
in 10% neutral-buffered formalin solution and later embed-
ded into paraffin. The lungs were then dissected and placed
in fresh paraformaldehyde for 48 h. Routine histological
techniques were used to paraffin-embed the tissue, 4-μm
paraffin sections were placed onto Fisher PLUS slides.
After deparaffinization and rehydration, 5 μm sections of
the lung tissue were stained with hematoxylin–eosin (HE),
dehydrated, and mounted.
The mean linear intercept, a measure of interalveolar
septal wall distance, was determined using a reticule with a
Thurlbeck grid comprising of 5 lines (each 550 mm long),
with 10 fields per section assessed at random. Two slides
per mouse were coded and analyzed using a reproducible
scoring system described elsewhere [26]. Fields with air-
ways or vessels were avoided by moving one field in any
one direction. Linear intercept (Lm) was calculated by
dividing the length of the line by the number of alveolar
wall and grid line interceptions. All counts were studied by
two independent observers in a blinded fashion.
Digital image analysis was performed on histological
sections, using Image-Pro Plus software version 5.0 (Me-
dia/cybernetics, Silver Springs, MD, USA), nuclear pro-
files in HE-stained sections were counted in the lamina
propria. The severity of inflammatory response was
expressed as the ratio of area of the cells to the whole
brochial surface area.
Real-time Reverse Transcription-Polymerase Chain
Reaction
RNA extracted from frozen stored the lung tissue
which collected at the time of dissection using an RNeasy
Mini kit (Qiagen). RNAyield was then amplified via PCR
using an Omniscript Reverse Transcriptase kit (Qiagen)
and stored at −80 °C until required. 0.5 μg per sample of
RNA was used to synthesize single-stranded complimen-
tary DNA (cDNA) using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, CA, USA) in a
PTC-200 Peltier Thermal Cycler (MJ Research, Water-
town, Mass., USA) according to manufacturer instructions.
The cDNAwas synthesized using the energic Scriptc DNA
synthesis kit (ShineGene Co., Ltd., Shanghai, China).
Real-time quantitative PCR (RT-qPCR) was performed
with a SYBRKit (Bioline). IL-17AmRNAwas quantitated
by real-time PCR (7300 Real-Time PCR Systems; Applied
Biosystems, Carlsbad, CA) using intron-spanning primers
(IL-17A sense, 5′-CCAGGGAGAGCTTCATCTGT-3′,
and antisense, 5′-AGGAAGTCCTTGGCCTCAGT-3′)
and SYBR-green detection. Cycling conditions were as
follows: step 1, 15 min at 95 °C; step 2, 20 s at 94 °C; step
3, 20 s at 55 °C; and step 4, 20 s at 72 °C, repeating step 2
to step 4, 55 times. RT-PCR results were analyzed with the
ΔΔCT method [36]. Gene expression was expressed as a
ratio of the gene of interest mRNA to GAPDH mRNA.
Western Blot Analysis
The lung tissues were homogenized using 1.4 mm
Precellys Ceramic beads and Precellys 24 homogenizer
(Peqlab, Erlangen, Germany) at 6800 rpm for 15 s and
cytosolic proteins were extracted with a hypotonic buffer
(active motif, part #100505) and detergent (active motif,
part #100512) by centrifugation at 14000 rpm for 30 s at
4 °C and qualified by bicinchoninic acid assay analysis.
Equal amounts of protein were separated by SDS-PAGE
and electrophoretically transferred to nitrocellulose mem-
brane and then incubated with primary antibodies against
phospho-p38 MAPK, total p38 MAPK, GR, and NF-κB
(Cell Signaling Technology, Beverly, CA) for blot
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detection. Final protein concentration was determined us-
ing a protein assay.
Statistical Analysis
Data are expressed as mean ± SEM. The statistical
analysis and graphics were performed using GraphPad
PRISM, version 5.0 (GraphPad Software, San Diego,
CA). One-way ANOVA with Bonferroni’s post hoc test
(for equal variance) or Dunnett’s T3 post hoc test (for
unequal variance) was performed for comparisons among
multiple groups. P < 0.05 was considered significant.
RESULTS
Total and Differential Cell Counts of BALF
BALF was collected 24 h after the last airway chal-
lenge of ozone-induced mice. As expected, compared with
PBS-treated ozone-exposed controls, numbers of total cells
in BALF were decreased significantly at 48 h after Dex
treatment, IL-17mAb treatment or vehicle compared with
the numbers after PBS-treated (P < 0.01, P < 0.01, and
P < 0.001, respectively) (Fig. 1a). Animals treated with
Dex and IL-17mAb showed a significant decrease com-
pared with Dex or IL-17mAb treatment alone in total cell
counts in BALF, but there was no statistical significance
(Fig. 1a). However, for neutrophils, only combined admin-
istration of IL-17mAb and dexamethasone on ozone-
exposed mice demonstrated significantly decreased in
counts in BALF compared with PBS-treated ozone-
exposed mice (P < 0.05) (Fig. 1b).
BALF and Serum Cytokine Levels
Ozone exposure in vehicle-treated mice evoked sig-
nificant decreases in IL-8 (in BALF and serum) (P < 0.001
and P < 0.05) (Fig. 2a, b). Similarly, IL-17mAb-treated
mice exposed to ozone exhibited significant decrease in
IL-8 in BALF compared with PBS-treated ozone-exposed
controls (P < 0.01) (Fig. 2a). There were significant differ-
ences in IL-17A in BALF after Dex treatment, IL-17mAb
treatment, or vehicle compared with mice exposed to
ozone after PBS-treated. Administration of IL-17mAb
and Dex or vehicle suggested significant reduction in IL-
17A in BALF compared with PBS-treated mice
(P < 0.001) (Fig. 2d). Whereas Dex-treated ozone-
exposed mice showed levels of IL-17A in serum were no
significantly changed compared with PBS-treated ozone-
exposed mice. Moreover, combined administration of IL-
17mAb and dexamethasone showed the inhibition of the
levels of IL-17A induced by IL-17mAb (Fig. 3e). As we
hypothesized previously, compared with the PBS-treated
controls, mice in the combined administration of IL-
17mAb and dexamethasone model exhibited the lower
levels of TNF-α (P < 0.05) (Fig. 2c). Whereas IL-17mAb
and Dex-treatment vehicle model showed higher levels of
IFN-γ in BALF than PBS-treated animals (P < 0.05)
(Fig. 2f), but there was no significant difference in treat-
ment effect between Dex-treated and vehicle models
(Fig. 2f).
The Airway InflammatoryCell InfiltrationDensity and
the Emphysema Score
There were significant differences in airway inflam-
matory cell infiltration density and the emphysema score in
the vehicle-treated models and the PBS-treated ozone-
Fig. 1. Mean numbers of total cells and neutrophils recovered from bronchoalveolar lavage fluid (BALF) of ozone-exposedmice. *P < 0.05, **P < 0.01, and
***P < 0.001, NEU neutrophils.
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exposed controls. In the ozone-exposed vehicle-treated
mice, airway inflammatory cell infiltration density and
the emphysema score were significantly lower than the
ozone-exposed PBS-treated mice (P < 0.001, P < 0.05, re-
spectively) (Fig. 3a, b). In addition, the airway inflamma-
tory cell infiltration density significantly decreased ozone-
exposed mice with IL-17mAb treatment only compared
with PBS-treated mice (P < 0.05, P < 0.05) (Fig. 3a). In
comparison with IL-17mAb or Dex only, the emphysema
score was not significantly different from PBS-treatedmice
(Fig. 3b).
IL-17A mRNA Levels in Lung Tissue
In the mice exposed to ozone, the mRNA levels of IL-
17A in the vehicle-treated mice were significantly de-
creased compared with PBS-treated mice (P < 0.01)
(Fig. 4a). However, In the Dex-treated mice exposed to
ozone, the expression of IL-17A mRNAwas higher com-
pared with PBS-treated mice (P < 0.05) (Fig. 4a). After the
vehicle-treatment, mice exposed to ozone exhibited signif-
icant decrease in the mRNA levels of IL-17A in
comparison with Dex-treated mice exposed to ozone
(P < 0.001) (Fig. 4a).
The Gene and Protein Expression of NF-κB and GR
and p38 MAPK Phosphorylation
Combined administration of IL-17mAb and dexa-
methasone on ozone-exposed mice significantly decreased
the expression of NF-κB compared with PBS-treated mice,
Dex-treated mice, IL-17mAb mice (P < 0.001, P < 0.01,
and P < 0.05, respectively) (Fig. 4b), but not between
PBS-treated or Dex-treated or IL-17mAb mice exposed
to ozone and PBS-treated mice exposed to ozone (Fig. 4b).
Similarly, compared with PBS-treated mice, Dex-treated
mice, and IL-17mAbmice, combined administration of IL-
17 mAb and dexamethasone on ozone-exposed mice sig-
nificantly increased the expression of GR (P < 0.001,
P < 0.001, P < 0.01, respectively) (Fig. 4c).
The p38MAPK phosphorylation was significantly
decreased in combined administration of IL-17mAb and
dexamethasone models as well as Dex-treated mice and IL-
17mAb mice (P < 0.001, P < 0.01, and P < 0.01,
Fig. 2. Mean levels of IL-8 (a in BALF and b in serum), TNF-α in BALF (c), IL-17A (d in BALF and e in serum), and IFN-γ in BALF (f) of ozone-exposed
mice. *P < 0.05, **P < 0.01, and ***P < 0.001.
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respectively) (Fig. 4d). However, combined administration
of IL-17mAb and dexamethasone on ozone-exposed mice
had a lower level of p38MAPK phosphorylation than Dex-
treated mice and IL-17mAb mice but was not significantly
changed (Fig. 4d).
DISCUSSION
The novel points in our current work are as follows:
on the one hand, though the inhibition of monotherapy of
IL-17mAb in ozone-induced airway inflammation has
been investigated, combination administration of IL-
17mAb and dexamethasone was used for the first time to
demonstrate its combined effects on inhibiting ozone-
induced airway inflammation and provided profound sup-
pression of a range of inflammatorymediators produced by
ozone exposure; on the other hand, we surprisingly found
that glucocorticoid insensitivity may due to the potential
increase in the production and transcription of IL-17A
induced by glucocorticoids.
Glucocorticoids suppress inflammatory gene tran-
scription by forming a complex with the glucocorticoid
receptor (GR) that inhibits the function of transcription
factors such as nuclear factor (NF)-κB, a process known
as transrepression [17]. Down-regulation of the expression
of GR results in glucocorticoids insensitivity and up-
regulation of the expression of GR could partly reverse
glucocorticoids insensitivity. Glucocorticoids insensitivity
may result from the reduced numbers and the attenuated
activation of GR. Some cytokines such as TNF-α and IL-1
are known to down-regulate GR expression and attenuate
the cell’s response to steroids [35, 52]. The involvement of
p38MAPK is associated with ozone exposure on the
Fig. 3. Mean value of airway inflammatory cell infiltration density in the lungs of ozone-exposed mice (a). Mean linear intercept (Lm) in the lungs of ozone-
exposed mice (b). *P < 0.05, **P < 0.01, and ***P < 0.001. Representative histological sections of airways with inflammatory cell infiltration (c) (×400) and
enlargement of alveolar spaces (d) (×100).
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response to glucocorticoid in a mouse model of asthma and
inhibiting the phosphorylation of p38MAPK could im-
prove the response to glucocorticoid and reverse the airway
inflammation [4]. IFN-γ reverses steroid response via in-
hibition of p38 MAPK pathway. Inhibiting p38MAPK
may potentially reverse steroid insensitivity. IFN-γ could
be a potential inhibitor of cytokine-induced p38MAPK
activation and that IFN-γ is critical to maintain corticoste-
roid sensitivity [18]. Our study presented that combination
administration significantly enhanced the expression of
GR and IFN-γ, decreased the expression of TNF-α,
p38MAPK, and NF-κB. But monotherapy did not alter
the expression of IFN-γ and TNF-α.
There are various indications that IL-17A may be
involved in the glucocorticoids insensitivity [37, 59]. IL-
8 [7, 34] and IL-17A [43] contribute to the recruitment of
neutrophils. To our knowledge, IL-17A can be found in the
human sputum, BALF, and peripheral blood. Increasing
evidence suggests that IL-17A significantly stimulates neu-
trophil maturation, migration, and function, and acts direct-
ly on the epithelial cells, airway fibroblasts, and smooth
muscle cells to induce the production of chemokines and
other cytokines, such as TNF-α, which recruit neutrophils
and monocytes into the airways and lung which promote
and worsen the neutrophilic inflammation status [9, 19, 21,
24, 29, 39]. Lung neutrophils show reduced expression of
the glucocorticoid receptors [38]. The effects of glucocor-
ticoids on cytokine production from airway neutrophils are
reduced. Increased numbers of airway neutrophils lacking
GR may contribute to glucocorticoid resistance in COPD
patients. Inflammation itself might contribute to reduced
glucocorticoids sensitivity [51]. Moreover, Th17-induced
Fig. 4. Expression of IL-17A mRNA (a) in the lung tissue of ozone-exposed mice. Western blot analysis of ratios of NF-κB (b), glucocorticoid receptors
(GR) (c), and phosphorylated p38 MAPK to total P38 MAPK (d) in the lung tissue in four groups of ozone-exposed mice. *P < 0.05, **P < 0.01, and
***P < 0.001.
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neutrophilic airway inflammation in mice was reported to
be glucocorticoids insensitive [32]. IL-17A reduced
HDAC activity, overexpression of HDAC2 reversed IL-
17A-induced glucocorticoids insensitivity [59], in other
words, inhibiting the expression of IL-17A, in turn increas-
ing HDAC2 activity, and glucocorticoids insensitivity will
be partly halted. The reduction of HDAC2 activity contrib-
utes to the transcription of NF-κB and enhances the activ-
ities of proinflammatory cytokines such as IL-8 and TNF-
α [20]. TNF-α is a potent pro-inflammatory cytokine
released by the cells of the immune system upon stimula-
tion [49] and is associated with GR and points to an
intricate interplay with GR signaling [51]. There are previ-
ous data from COPD alveolar macrophages that IL-8 is
glucocorticoids insensitivity [15, 16].
There are previous data from COPD alveolar macro-
phages that IL-17A induced IL-8 production is glucocorti-
coids insensitivity [15, 16, 21]. These previous studies add
further weight to another finding that macrophage IL-8 pro-
duction is glucocorticoids insensitive [23]. Prior studies
have showed that IL-17A increases the release of IL-8 from
the bronchial epithelial, and IL-17A may increase human
neutrophil recruitment through IL-8 in vitro. IL-17A can
also stimulate the production of pro-inflammatory cyto-
kines IL-1β and TNF-α, which can synergize with IL-
17A [25, 31, 43]. These modifications and various pro-
cesses regulated by IL-17A are shown to be involved in the
glucocorticoids insensitivity, but it is still unknown wheth-
er there might be a direct relationship exists between IL-
17A and glucocorticoids insensitivity.
In our study, we determined whether the administra-
tion of IL-17mAb affects the response of corticosteroids on
chronic lung inflammation and emphysema induced by
ozone exposure. Remarkably, we conclude that dexameth-
asone had no effect in altering the number of neutrophils,
Lm, IL-8, IL-17A, TNF-α, IFN-γ, GR, and the increased
expression of NF-κB induced by chronic ozone exposure.
Some effects of dexamethasone were observed on the num-
ber of total inflammatory cells and the airway inflammatory
cell infiltration density, but it is also observed in IL-17mAb
treated group. In addition, we have also shown that gluco-
corticoids induced the increase of the production of IL-17A
and the expression of IL-17A mRNA induced by chronic
exposure to ozone. Combined administration of IL-17mAb
and dexamethasone on ozone-exposed mice significantly
decreased the expression of IL-17A mRNA and NF-κB
compared with monotherapy of dexamethasone, which
was consistent with reduced pro-inflammatory cytokine
production and increased GR expression. These data may
therefore strengthen the view that a potential increase in the
production of systemic IL-17A and the expression of IL-
17A gene transcription may be a cause of corticosteroids
insensitivity and account for IL-17A inhibitor partly revers-
ing the glucocorticoids insensitivity. This could also indi-
rectly explain why glucocorticoids do not work well in
certain COPD populations suggesting reduced sensitivity.
Compared with the monotherapy responses, the re-
duced inflammatory cytokines (IL-8, IL-17A, and TNF-α)
have been observed after the combined administration of
IL-17mAb and dexamethasone. Moreover, neutrophils in
BALF were not significantly altered after dexamethasone
or IL-17mAb treatment alone. However, combined admin-
istration of IL-17mAb and dexamethasone on ozone-
exposed mice exhibited a significant decrease in the total
inflammatory cells and neutrophils in BALF and signifi-
cantly decreased the airway inflammatory cell infiltration
density than the single IL-17mAb treated group compared
with the PBS model. In addition, we observed that in the
chronic exposure model to an oxidant, ozone, the combi-
nation administration of IL-17 mAb, and dexamethasone
ameliorates the induction of emphysema, and this was not
seen in the monotherapy of dexamethasone or IL-17mAb
response, which is in agreement with our previous work
[57]. This indicated that IL-17A was not involved in the
induction of emphysema but contributed to increase the
effect of corticosteroids on attenuating the emphysema.
To further investigate for a special effect of combined
administration, we detected the Th1-driven cytokine IFN-γ
in BALF. Here, we demonstrated that combination admin-
istration increased the levels of IFN-γ, a prominent product
of CD8+ cells, but decreased the induction of emphysema
with alveolar enlargement, which is likely to be
inconsistent with the previous studies that overexpression
of IFN-γ led to emphysema and enhanced neutrophil-rich
inflammation in the adult murine lung [55]. Nevertheless,
whether and how IFN-γ modulates emphysema and in-
flammation needs further investigation.
Combined with the previous work we have finished
[57], we have shown that chronic exposure to ozone indu-
ces lung emphysema and inflammation as previously de-
scribed, and in the present study, we also demonstrated the
fact that in glucocorticoid-treated mice exposed to ozone,
the level of systematic IL-17Awas higher, compared with
that of the controls, which was different from what was
previously reported. Similarly, we also confirmed the find-
ing in the expression of IL-17A mRNA.
As mentioned above, we concluded that IL-17 mAb
was comparable to glucocorticoids in the role of certain
anti-inflammation, and combination administration of IL-
17mAb and glucocorticoids have profound anti-
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inflammatory effects on ozone-induced airway inflamma-
tion and partly restore glucocorticoid sensitivity (reestab-
lish the beneficial effects of glucocorticoids). For IL-17A
inhibitors in clinical development, these data provide a
strong rational for combination trials with glucocorticoids
and provide partial benefit in reversing the glucocorticoids
insensitivity.
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